J Lipid Atheroscler.  2023 Jan;12(1):47-57. 10.12997/jla.2023.12.1.47.

Pyruvate Dehydrogenase Complex and Glucose Oxidation as a Therapeuti

• Dakhili SAT
• Greenwell AA
• Ussher JR

• KMID: 2539216
• DOI: http://doi.org/10.12997/jla.2023.12.1.47

Abstract

Diabetic cardiomyopathy was originally described as the presence of ventricular dysfunction in the absence of coronary artery disease and/or hypertension. It is characterized by diastolic dysfunction and is more prevalent in people with diabetes than originally realized, leading to the suggestion in the field that it simply be referred to as diabetic heart disease. While there are currently no approved therapies for diabetic heart disease, a multitude of studies clearly demonstrate that it is characterized by several disturbances in myocardial energy metabolism. One of the most prominent changes in myocardial energy metabolism in diabetes is a robust impairment in glucose oxidation. Herein we will describe the mechanisms responsible for the diabetes-induced decline in myocardial glucose oxidation, and the pharmacological approaches that have been pursued to correct this metabolic disorder. With surmounting evidence that stimulating myocardial glucose oxidation can alleviate diastolic dysfunction and other pathologies associated with diabetic heart disease, this may also represent a novel strategy for decreasing the prevalence of heart failure with preserved ejection fraction in the diabetic population.

Keyword

Diabetic cardiomyopathies; Diabetic heart disease; Diastolic dysfunction; Cardiac energetics; Pyruvate dehydrogenase; Glucose oxidation